FDA review uncertainty, failed phase 3 for ersodetug in HI, high-risk upLIFT trial, tight cash runway—read more macro ...
In order to evaluate the effect of total parenteral nutrition associated with glutamine and enteral fluid therapy, associated or not with glutamine, on the lipidogram of horses subjected to starvation ...
17d
CorMedix CEO touts Melinta pivot, DefenCath TDAPA transition and Q2 REZZAYO Phase 3 data at Leerink
Chief Executive Officer Joseph Todisco told attendees at the Leerink Global Healthcare Conference that the company has ...
17d
CorMedix Touts Q2 REZZAYO Data, Melinta Integration and DefenCath Reimbursement Shift at Conference
CorMedix (NASDAQ:CRMD) executives used a presentation at the Citizens Life Sciences Conference to outline the company’s focus ...
China's healthcare system may benefit from the integration of home infusion therapy (HIT) combined with home health services (HHS) to address the urgent need for a sustainable long-term, post-acute ...
China’s healthcare system is confronting a rising burden of antimicrobial resistance, chronic complex diseases, and an aging population requiring long-term, post-acute care. As a value-based care ...
Fresenius sent a letter to customers in November warning them about the problem. The FDA classified the recall a month later as Class I, its highest risk category, according to an enforcement report.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results